Buradasınız

Anasayfa » Content

HİPERTANSİYONUN RENAL KOMPLİKASYONLAR VE BÖBREK HASTALIĞININ PROGRESYONUNDAKİ ROLÜ

THE ROLE OF HYPERTENSION IN RENAL COMPLICATIONS AND PROGRESSION OF RENAL DAMAGE

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The risk of hypertension induced renal damage sufficient to result in ESRD is a broad spectrum problem. The risk is relatively small in the general population with essential hypertension in the absence of malignant nephrosclerosis;it is increased substantially in certain populations and is gretatest in patients with co-existent chronic renal disease and/or diabetes, particularly if they belong to a susceptible racial/ethnic group. Hypertension is estimated to be present in 90% of patients with end stage renal disease. Antihypertensive theraphy is the cornerstone of renoprotection. Angiotensin II is a main mediator of glomerular hemodynamic adaptation in renal damage. Most of the antihypertensive agents (except dihydropyridines) have a similar protecting effect on the kidney if optimal blood pressure is obtained. Recent data have suggested more agressive blood pressure control exhibited a strongrenoprotective effect
Bookmark/Search this post with
Abstract (Original Language): 
Hipertansiyona bağlı böbrek yetmezliği gelişimi riski, esansiyelhipertansiyonu olan hastalarda çok düşük ve tartışılan bir ilişki iken, bazı hasta gruplarında bu risk artmakta; eşlik eden renal hastalık ve diabet varlığında ise özellikle bazı etnik gruplarda bu ilişki güçlenmektedir. Kompanse böbrek yetmezliği olan hastalarda renal hastalığın progresyonu ile paralel olarak hipertansiyon oranı artmaktadır. Bu oran diyalize başlayanlarda %90'a ulaşmaktadır. Antihipertansif tedavi renal koruyucu girişimlerin temel taşını oluşturmaktadır Angiotensin II progresif renal hasarlanmada glomerüler hemodinamik değişikliklere yol açan ana mediatördür. Etkin kan basıncı kontrolü sağladığında, bir çok antihipertansif ajanın (dihidropridinler hariç) böbrek üzerine benzer koruyucu etkisi bulunmaktadır. Son yıllarda daha agresif kan basıncı kontrolünün renoprotektif etkiyi güçlendireceğine dair veriler artmaktadır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_427.pdf
  • 2
67-73
  • Turkish

REFERENCES

References: 

1. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?
Kidney Int 1990;38:384-94.
2. Remuzzi G. Nephropathic nature of proteinuria. Current Opinion in Nephrology and Hypertension 1999;8:655-663
3. Chi-yuan Hsu. Does non-malignant hypertension cause renal insufficiency? Evidence based perspective. Current Opinion in Nephrology and Hypertension 2002;11:267-72.
15. Fisberg A M. Hypertension and nephritis 5th edition,
Philadelphia, Lea and Febiger 1956:283,678,807¬809,821.
16. Bakir A A, Dunea G. Renal disease in the inner city.
Seminars in Nephrology 2001;21(4):334-345.
17. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to
hypertension. Am J Kidney Dis 1994;23(5):655-60
18. Perry HM Jr, Miller JP, Fornoff JR, et al. Early
72
predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-94.
19. Klag M J, Whelton P. K, Randall B L, et al. Blood Pressure and End-Stage Renal Disease in Men. N Engl J Med 1996;334:13-18.
20. Nenov V D, Taal M W, Sakharova O V, Brenner B M. Multi-hit nature of chronic renal disease. Current Opinion in Nephrology and Hypertension 2000;9:85-97.
21. Barker D J, Bull A R, Osmond C, et al. Fetal and placental size and risk of hypertension in adult life.
BMJ 1990;301:259-262.
22. Kocks M J A, Zeeuw D, Navis G J. Optimal blood
pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanism of response variability. Current Opinion in Nephrology and Hypertension 2002;l 1:135-140.
23. Laing C, Unwin R J. Are calcium antagonists effective in preventing complications of hypertension and progression of renal disease? Current Opinion in
Nephrology and Hypertension 2000;9:489-495.
24. Bidani A K, Griffin K A. Calcium channel blockers and renal protection: Is there an optimal dose? J Lab Clin
Med 1995;125:553-555.
25. Bleyer A J, Appel R G. Risk factors associated with hypertensive nephrosclerosis. Nephron 1999;82:193-8.
26. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease
Study. Ann Intern Med 1995;123(Suppl 10):754-62.

Thank you for copying data from http://www.arastirmax.com